Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Susceptibility of Pseudomonas aeruginosa recovered from cystic fibrosis patients to murepavadin and thirteen comparator antibiotics.

Ekkelenkamp MB, Cantón R, Díez-Aguilar M, Tunney MM, Gilpin DF, Bernardini F, Dale GE, Elborn JS, Bayjanov JR, Fluit A.

Antimicrob Agents Chemother. 2019 Nov 25. pii: AAC.01541-19. doi: 10.1128/AAC.01541-19. [Epub ahead of print]

PMID:
31767727
2.

Whole genome analysis of Pandoraea species strains from cystic fibrosis patients.

Bayjanov JR, Ekkelenkamp MB, Rogers MR, Cantón R, Benaissa-Trouw BJ, Díez-Aguilar M, Tunney M, Fluit AC.

Future Microbiol. 2019 Nov 25. doi: 10.2217/fmb-2019-0038. [Epub ahead of print]

PMID:
31762328
3.

Multifaceted intervention to Reduce Antimicrobial Prescribing in Care Homes: a process evaluation of a UK-based non-randomised feasibility study.

Potter R, Campbell A, Ellard DR, Shaw C, Gardner E, Agus A, O'Reilly D, Underwood M, Loeb M, Stafford B, Tunney M, Hughes C.

BMJ Open. 2019 Nov 21;9(11):e032185. doi: 10.1136/bmjopen-2019-032185.

4.

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

Loebinger MR, Polverino E, Blasi F, Elborn SJ, Chalmers JD, Tiddens HA, Goossens H, Tunney M, Zhou W, Angyalosi G, Hill AT, Haworth CS; iBEST-1 Trial Team.

Pulm Pharmacol Ther. 2019 Oct;58:101834. doi: 10.1016/j.pupt.2019.101834. Epub 2019 Aug 18.

PMID:
31433997
5.

Composition of airway bacterial community correlates with chest HRCT in adults with bronchiectasis.

O'Neill K, Einarsson GG, Rowan S, McIlreavey L, Lee AJ, Lawson J, Lynch T, Horsley A, Bradley JM, Elborn JS, Tunney MM.

Respirology. 2019 Jul 30. doi: 10.1111/resp.13653. [Epub ahead of print]

PMID:
31364220
6.

A general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans.

Fathy Mohamed Y, Scott NE, Molinaro A, Creuzenet C, Ortega X, Lertmemongkolchai G, Tunney MM, Green H, Jones AM, DeShazer D, Currie BJ, Foster LJ, Ingram R, De Castro C, Valvano MA.

J Biol Chem. 2019 Sep 6;294(36):13248-13268. doi: 10.1074/jbc.RA119.009671. Epub 2019 Jul 26.

PMID:
31350337
7.

Community analysis and co-occurrence patterns in airway microbial communities during health and disease.

Einarsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, Elborn JS.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00128-2017. doi: 10.1183/23120541.00128-2017. eCollection 2019 Jul.

8.

Draft Genome Sequence of Haemophilus haemolyticus Strain 16/010 O, Isolated from a Sputum Sample from a Cystic Fibrosis Patient.

Fluit AC, Bayjanov JR, Tunney M, Elborn JS, Rogers MRC, Schürch AC, Ekkelenkamp MB.

Microbiol Resour Announc. 2019 Jun 6;8(23). pii: e00243-19. doi: 10.1128/MRA.00243-19.

9.

Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

Sherrard LJ, Einarsson GG, Johnston E, O'Neill K, McIlreavey L, McGrath SJ, Gilpin DF, Downey DG, Reid A, McElvaney NG, Boucher RC, Muhlebach MS, Elborn JS, Tunney MM.

J Cyst Fibros. 2019 Mar 21. pii: S1569-1993(19)30052-9. doi: 10.1016/j.jcf.2019.02.012. [Epub ahead of print]

PMID:
30905581
10.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
11.

British Thoracic Society guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher WP, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

BMJ Open Respir Res. 2018 Dec 28;5(1):e000348. doi: 10.1136/bmjresp-2018-000348. eCollection 2018.

12.

Interventions to Improve Antimicrobial Stewardship for Older People in Care Homes: A Systematic Review.

Nguyen HQ, Tunney MM, Hughes CM.

Drugs Aging. 2019 Apr;36(4):355-369. doi: 10.1007/s40266-019-00637-0.

PMID:
30675682
13.

British Thoracic Society Guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher PW, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

Thorax. 2019 Jan;74(Suppl 1):1-69. doi: 10.1136/thoraxjnl-2018-212463. No abstract available.

PMID:
30545985
14.

The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis?

Héry-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM.

J Cyst Fibros. 2019 Jan;18(1):13-21. doi: 10.1016/j.jcf.2018.11.003. Epub 2018 Nov 25. Review.

PMID:
30487080
15.

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.

Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Stuart Elborn J, Tunney MM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3218. doi: 10.1093/jac/dky313. No abstract available.

PMID:
30351435
16.

Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.

Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Merino I, de Dios Caballero J, Jones M, van Westreenen M, Tunney MM, Cantón R, Fluit AC.

Int J Antimicrob Agents. 2019 Jan;53(1):84-88. doi: 10.1016/j.ijantimicag.2018.09.001. Epub 2018 Sep 19.

PMID:
30240837
17.

Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputum.

Tunney MM, Payne JE, McGrath SJ, Einarsson GG, Ingram RJ, Gilpin DF, Juarez-Perez V, Elborn JS.

J Antimicrob Chemother. 2018 Dec 1;73(12):3391-3397. doi: 10.1093/jac/dky357.

PMID:
30219825
18.

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.

Muhlebach MS, Hatch JE, Einarsson GG, McGrath SJ, Gilipin DF, Lavelle G, Mirkovic B, Murray MA, McNally P, Gotman N, Davis Thomas S, Wolfgang MC, Gilligan PH, McElvaney NG, Elborn JS, Boucher RC, Tunney MM.

Eur Respir J. 2018 Jul 11;52(1). pii: 1800242. doi: 10.1183/13993003.00242-2018. Print 2018 Jul.

19.

Criteria required for an acceptable point-of-care test for UTI detection: Obtaining consensus using the Delphi technique.

Weir NM, Pattison SH, Kearney P, Stafford B, Gormley GJ, Crockard MA, Gilpin DF, Tunney MM, Hughes CM.

PLoS One. 2018 Jun 7;13(6):e0198595. doi: 10.1371/journal.pone.0198595. eCollection 2018.

20.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

21.

Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis.

O'Neill K, Bradley JM, Reid A, Downey DG, Rendall J, McCaughan J, Moore JE, Tunney MM, Elborn JS.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701704. doi: 10.1183/13993003.01704-2017. Print 2018 Feb. No abstract available.

22.

CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.

Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, O'Callaghan G, Shanahan F, Murphy DM, O'Connor OJ, Shortt CA, Tunney MM, Eustace JA, Maher MM, Elborn JS, Plant BJ.

Chest. 2018 Feb;153(2):395-403. doi: 10.1016/j.chest.2017.10.005. Epub 2017 Oct 14.

PMID:
29037527
23.

Novel freeze-dried DDA and TPGS liposomes are suitable for nasal delivery of vaccine.

Yusuf H, Ali AA, Orr N, Tunney MM, McCarthy HO, Kett VL.

Int J Pharm. 2017 Nov 25;533(1):179-186. doi: 10.1016/j.ijpharm.2017.09.011. Epub 2017 Sep 6.

PMID:
28887219
24.

Training in multiple breath washout testing for respiratory physiotherapists.

O'Neill K, Elborn JS, Tunney MM, O'Neill P, Rowan S, Martin S, Bradley JM.

Physiotherapy. 2018 Mar;104(1):61-66. doi: 10.1016/j.physio.2017.04.003. Epub 2017 Apr 25.

PMID:
28822601
25.

Characterisation of eppin function: expression and activity in the lung.

Scott A, Glasgow A, Small D, Carlile S, McCrudden M, McLean D, Brown R, Doherty D, Lundy FT, Hamid UI, O'Kane CM, McAuley DF, Brodlie M, Tunney M, Elborn JS, Irwin CR, Timson DJ, Taggart CC, Weldon S.

Eur Respir J. 2017 Jul 13;50(1). pii: 1601937. doi: 10.1183/13993003.01937-2016. Print 2017 Jul.

26.

Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosa.

Pattison SH, Gibson DS, Johnston E, Peacock S, Rivera K, Tunney MM, Pappin DJ, Elborn JS.

Eur Respir J. 2017 Jul 5;50(1). pii: 1601569. doi: 10.1183/13993003.01569-2016. Print 2017 Jul.

27.

Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.

Payne JE, Dubois AV, Ingram RJ, Weldon S, Taggart CC, Elborn JS, Tunney MM.

Int J Antimicrob Agents. 2017 Sep;50(3):427-435. doi: 10.1016/j.ijantimicag.2017.04.014. Epub 2017 Jun 27.

PMID:
28666755
28.

Evidence of persistence of Prevotella spp. in the cystic fibrosis lung.

Gilpin DF, Nixon KA, Bull M, McGrath SJ, Sherrard L, Rolain JM, Mahenthiralingam E, Elborn JS, Tunney MM.

J Med Microbiol. 2017 Jun 13. doi: 10.1099/jmm.0.000500. [Epub ahead of print]

PMID:
28604331
29.

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients.

Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plésiat P, Traore H, Tulkens PM, Vanderbist F, Van Bambeke F.

Eur Respir J. 2017 May 19;49(5). pii: 1601847. doi: 10.1183/13993003.01847-2016. Print 2017 May.

30.

Antibiotic susceptibility of planktonic- and biofilm-grown staphylococci isolated from implant-associated infections: should MBEC and nature of biofilm formation replace MIC?

Brady AJ, Laverty G, Gilpin DF, Kearney P, Tunney M.

J Med Microbiol. 2017 Apr;66(4):461-469. doi: 10.1099/jmm.0.000466.

PMID:
28463662
31.

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis.

Vallières E, Tumelty K, Tunney MM, Hannah R, Hewitt O, Elborn JS, Downey DG.

Eur Respir J. 2017 Apr 12;49(4). pii: 1600851. doi: 10.1183/13993003.00851-2016. Print 2017 Apr. No abstract available.

32.

Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.

O'Neill K, Moran F, Tunney MM, Elborn JS, Bradbury I, Downey DG, Rendall J, Bradley JM.

BMJ Open Respir Res. 2017 Jan 12;4(1):e000168. doi: 10.1136/bmjresp-2016-000168. eCollection 2017.

33.

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.

Chalhoub H, Pletzer D, Weingart H, Braun Y, Tunney MM, Elborn JS, Rodriguez-Villalobos H, Plésiat P, Kahl BC, Denis O, Winterhalter M, Tulkens PM, Van Bambeke F.

Sci Rep. 2017 Jan 16;7:40208. doi: 10.1038/srep40208.

34.

Chronic lung disease in common variable immune deficiency (CVID): A pathophysiological role for microbial and non-B cell immune factors.

Mooney D, Edgar D, Einarsson G, Downey D, Elborn S, Tunney M.

Crit Rev Microbiol. 2017 Aug;43(4):508-519. doi: 10.1080/1040841X.2016.1268568. Epub 2017 Jan 10. Review.

PMID:
28068853
35.

Response.

O'Neill K, Elborn JS, Tunney MM, Bradley JM.

Chest. 2016 Dec;150(6):1413-1414. doi: 10.1016/j.chest.2016.09.037. No abstract available.

PMID:
27938757
36.

Corrigendum to 'Efficacy of a standard meticillin-resistant Staphylococcus aureus decolonisation protocol in routine clinical practice' [Journal of Hospital Infection (2010) 93-98].

Gilpin DF, Small S, Bakshi S, Kearney MP, Cardwell C, Tunney MM.

J Hosp Infect. 2016 Dec;94(4):411. doi: 10.1016/j.jhin.2016.07.018. Epub 2016 Oct 19. No abstract available.

PMID:
27771148
37.

MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Vallières E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG.

ERJ Open Res. 2016 Mar 15;2(1). pii: 00064-2015. eCollection 2016 Jan.

38.

Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Mustafa MH, Chalhoub H, Denis O, Deplano A, Vergison A, Rodriguez-Villalobos H, Tunney MM, Elborn JS, Kahl BC, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6735-6741. doi: 10.1128/AAC.01046-16. Print 2016 Nov.

39.

The role of anaerobic bacteria in the cystic fibrosis airway.

Sherrard LJ, Bell SC, Tunney MM.

Curr Opin Pulm Med. 2016 Nov;22(6):637-43. doi: 10.1097/MCP.0000000000000299. Review.

PMID:
27455453
40.

Lung Clearance Index in Adults and Children With Cystic Fibrosis.

O'Neill K, Tunney MM, Johnston E, Rowan S, Downey DG, Rendall J, Reid A, Bradbury I, Elborn JS, Bradley JM.

Chest. 2016 Dec;150(6):1323-1332. doi: 10.1016/j.chest.2016.06.029. Epub 2016 Jul 6.

PMID:
27395423
41.

Eradication and phenotypic tolerance of Burkholderia cenocepacia biofilms exposed to atmospheric pressure non-thermal plasma.

Alshraiedeh NH, Higginbotham S, Flynn PB, Alkawareek MY, Tunney MM, Gorman SP, Graham WG, Gilmore BF.

Int J Antimicrob Agents. 2016 Jun;47(6):446-50. doi: 10.1016/j.ijantimicag.2016.03.004. Epub 2016 Apr 22.

PMID:
27179816
42.

Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers.

Einarsson GG, Comer DM, McIlreavey L, Parkhill J, Ennis M, Tunney MM, Elborn JS.

Thorax. 2016 Sep;71(9):795-803. doi: 10.1136/thoraxjnl-2015-207235. Epub 2016 May 4.

PMID:
27146202
43.

Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota.

Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Elborn JS, Tunney MM.

Int J Antimicrob Agents. 2016 Feb;47(2):140-5. doi: 10.1016/j.ijantimicag.2015.12.004. Epub 2015 Dec 29.

44.

Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis Outcomes.

Shteinberg M, Rivlin J, Gur M, Konopnicki M, Stein N, Tunney MM, Elborn JS, Downey DG, Johnston E, Shalom H, Levy A.

Lung. 2015 Dec;193(6):1017-21. doi: 10.1007/s00408-015-9801-z. Epub 2015 Sep 14.

PMID:
26370551
45.

The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway.

Mirković B, Murray MA, Lavelle GM, Molloy K, Azim AA, Gunaratnam C, Healy F, Slattery D, McNally P, Hatch J, Wolfgang M, Tunney MM, Muhlebach MS, Devery R, Greene CM, McElvaney NG.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1314-24. doi: 10.1164/rccm.201505-0943OC.

46.

Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis.

O'Neill K, Bradley JM, Johnston E, McGrath S, McIlreavey L, Rowan S, Reid A, Bradbury I, Einarsson G, Elborn JS, Tunney MM.

PLoS One. 2015 May 20;10(5):e0126980. doi: 10.1371/journal.pone.0126980. eCollection 2015.

47.

Predictors of adherence to treatment in bronchiectasis.

McCullough AR, Tunney MM, Stuart Elborn J, Bradley JM, Hughes CM.

Respir Med. 2015 Jul;109(7):838-45. doi: 10.1016/j.rmed.2015.04.011. Epub 2015 Apr 25.

48.

Microbiology review series: CF microbiology - -Towards 2020 and beyond.

Rogers GB, Tunney MM.

J Cyst Fibros. 2015 May;14(3):289-90. doi: 10.1016/j.jcf.2015.03.016. Epub 2015 Apr 12. No abstract available.

49.

Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis.

Boutin S, Graeber SY, Weitnauer M, Panitz J, Stahl M, Clausznitzer D, Kaderali L, Einarsson G, Tunney MM, Elborn JS, Mall MA, Dalpke AH.

PLoS One. 2015 Jan 28;10(1):e0116029. doi: 10.1371/journal.pone.0116029. eCollection 2015.

50.

Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.

Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, Kahl BC, Van Bambeke F, Tulkens PM.

J Antimicrob Chemother. 2015 May;70(5):1596-8. doi: 10.1093/jac/dku551. Epub 2015 Jan 14. No abstract available.

PMID:
25587996

Supplemental Content

Loading ...
Support Center